List of Excipients in Branded Drug NICORETTE 4MG CINNAMON SURGE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lil' Drug Store products Inc	NICORETTE 4MG CINNAMON SURGE	nicotine polacrilex	66715-8123	ACACIA
Lil' Drug Store products Inc	NICORETTE 4MG CINNAMON SURGE	nicotine polacrilex	66715-8123	ACESULFAME POTASSIUM
Lil' Drug Store products Inc	NICORETTE 4MG CINNAMON SURGE	nicotine polacrilex	66715-8123	ALUMINUM OXIDE
Lil' Drug Store products Inc	NICORETTE 4MG CINNAMON SURGE	nicotine polacrilex	66715-8123	CARNAUBA WAX

NICORETTE 4 mg Cinnamon Surge Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

NICORETTE 4 mg Cinnamon Surge is a nicotine polacrilex lozenge for adults seeking smoking cessation. Its commercial position depends on rapid nicotine delivery, cinnamon flavor acceptance, mouthfeel, shelf stability, and adherence to the U.S. OTC nicotine-replacement framework. The excipient platform is relatively accessible to generic manufacturers, so differentiation is more likely to come from taste, dissolution, packaging, supply reliability, and regulatory execution than from broad composition-of-matter protection.

Product basis: U.S. nicotine polacrilex lozenge, 4 mg nicotine equivalent, cinnamon flavor. The analysis uses the U.S. product and FDA OTC framework.

What excipients are used in NICORETTE 4 mg Cinnamon Surge?

The public product labeling identifies nicotine polacrilex as the active ingredient and lists a conventional lozenge excipient system.

Component	Functional role
Nicotine polacrilex	Ion-exchange resin complex that controls nicotine release and reduces the handling of free nicotine
Mannitol	Bulking agent, sweetener, cooling-mouthfeel contributor and low-calorie carrier
Sodium alginate	Binder and matrix former; supports lozenge integrity and dissolution control
Xanthan gum	Rheology modifier and binder; supports matrix structure
Sodium carbonate	Alkalinizing agent that promotes nicotine release from the resin complex and increases buccal absorption
Acesulfame potassium	High-intensity sweetener that offsets nicotine bitterness
Magnesium stearate	Lubricant used during compression
Cinnamon flavor	Taste and aroma system intended to improve product acceptability

The formulation is designed for slow dissolution in the mouth rather than swallowing as an immediate-release tablet. The FDA label instructs users to allow the lozenge to dissolve slowly and not to chew or swallow it whole. Product performance therefore depends on the interaction between resin loading, alkalinity, matrix strength, saliva wetting and flavor release [1].

How does the NICORETTE excipient system support nicotine delivery?

The formulation has four commercial functions.

First, sodium carbonate raises local pH. Nicotine absorption across the buccal mucosa is favored when more nicotine is present in the unionized form. The alkalinizer must be strong enough to support absorption without producing excessive irritation or an unpleasant alkaline taste.

Second, sodium alginate and xanthan gum create a compressed matrix. The gums help prevent the lozenge from disintegrating too rapidly, while saliva gradually hydrates the tablet and releases nicotine polacrilex.

Third, mannitol contributes to mouthfeel. Its cooling effect can reduce the perception of bitterness and harshness. It also avoids the dental and caloric profile associated with sucrose-based tablets.

Fourth, acesulfame potassium and cinnamon flavor compensate for nicotine’s bitterness and throat irritation. Flavor performance is particularly important because the lozenge remains in the mouth for an extended period.

The formulation must balance three competing targets:

1. Sufficiently slow dissolution for controlled use.
2. Sufficiently rapid nicotine liberation to reduce withdrawal symptoms.
3. Acceptable taste during the entire dissolution period.

What formulation patents protect NICORETTE 4 mg Cinnamon Surge?

The core active ingredient, nicotine, is long off-patent. Nicotine polacrilex and conventional nicotine lozenge technology are also mature technologies. Broad patent protection for the active ingredient or the general concept of a nicotine lozenge is unlikely to block competition.

The commercially relevant protection categories are narrower:

Protection category	Strategic relevance
Nicotine-resin complex composition	Potentially relevant only if a specific resin, loading level or release profile is claimed
Lozenge dissolution profile	Could protect a defined release window or nicotine-delivery performance
Flavor system	Potentially relevant for distinctive flavor combinations, masking systems or sustained flavor release
Manufacturing process	May cover compression, granulation, resin loading, moisture control or coating
Packaging	May protect child-resistant, unit-dose or moisture-barrier configurations
Trade dress and trademark	“NICORETTE” and “Cinnamon Surge” branding can be commercially significant even when formulation patents are weak
Method of use	Smoking-cessation use claims are constrained by the OTC regulatory framework and are unlikely to provide broad exclusionary rights by themselves

No broad, product-blocking patent position can be inferred from the public consumer label. The principal competitive barrier is regulatory compliance and brand equity, not an apparently impenetrable excipient patent estate.

What is the Orange Book status of NICORETTE 4 mg Cinnamon Surge?

NICORETTE 4 mg Cinnamon Surge is marketed as an OTC nicotine-replacement product under the FDA’s nonprescription smoking-cessation framework. The principal regulatory reference is the FDA OTC monograph for smoking-cessation products, together with product-specific labeling requirements [2].

The product should not be treated like a conventional prescription drug with a typical Orange Book patent-certification strategy. OTC monograph products generally do not create the same paragraph IV pathway that applies to an approved prescription NDA. A competitor can therefore pursue an OTC monograph-compliant product without necessarily filing an ANDA against a branded prescription product.

This changes the competitive analysis:

• Patent certification is less central than monograph compliance.
• Labeling, dosage, active ingredient, strength and route must conform to the applicable FDA requirements.
• A reformulated competitor may require a new regulatory pathway if it falls outside the monograph.
• Brand, flavor and packaging claims remain vulnerable to trademark, trade-dress and unfair-competition disputes.

When does NICORETTE lose exclusivity?

The active ingredient and broad dosage form have no meaningful modern exclusivity period. Market exclusivity is primarily commercial and brand-based.

Exclusivity component	Position
Nicotine active ingredient	Long off-patent
Nicotine polacrilex concept	Mature and broadly accessible
4 mg lozenge dosage form	Competitive OTC technology
Cinnamon flavor	Potentially differentiated through branding and formulation execution
NICORETTE trademark	Brand protection remains commercially important
OTC regulatory pathway	Provides compliance requirements, not conventional market exclusivity
Formulation-specific patents	Must be evaluated claim by claim; broad blocking rights are not evident from the public label

A generic or private-label manufacturer can compete by using nicotine polacrilex or another permitted nicotine delivery system, provided it meets FDA requirements. The most credible entry strategy is a flavor-matched, 4 mg OTC lozenge with comparable dissolution, clear labeling and lower retail pricing.

What generic entry risks exist for NICORETTE 4 mg Cinnamon Surge?

Generic entry risk is high at the product-technology level. It is lower at the brand-substitution level because nicotine lozenges are sensitive to taste, mouthfeel and perceived effectiveness.

Likely entry routes

1. Direct cinnamon lozenge competition.
   A manufacturer can replicate the major functional architecture: nicotine polacrilex, mannitol, alkalinizer, gums, sweetener, lubricant and cinnamon flavor.

2. Private-label store brands.
   Retailers can market lower-priced nicotine lozenges using the same therapeutic category while avoiding NICORETTE branding.

3. Flavor-led competition.
   Mint, fruit, cinnamon and unflavored products can capture users who dislike the branded cinnamon profile.

4. Alternative nicotine-replacement products.
   Nicotine gum, transdermal patches, oral sprays and nicotine pouches compete for the same cessation and craving-management consumer.

5. Combination regimens.
   Patch-plus-lozenge use can shift demand toward products positioned for breakthrough cravings rather than continuous nicotine replacement.

The principal risks to the brand are price erosion, retailer substitution, flavor parity and loss of shelf space. Patent litigation is less likely to be the primary barrier than trademark enforcement or disputes over therapeutic equivalence and labeling.

How strong is the patent estate for the formulation?

The formulation patent estate is likely moderate to weak for broad claims and stronger only for narrow implementation claims.

Strengths

• Nicotine-resin delivery can support detailed claims around resin chemistry, loading and release.
• Specific dissolution or absorption profiles may create narrower barriers.
• Flavor-masking and long-lasting flavor systems can be protectable if technically distinct.
• Manufacturing controls for moisture, compression force and dose uniformity can support process claims.

Weaknesses

• Mannitol, sodium carbonate, alginate, xanthan gum and magnesium stearate are standard pharmaceutical excipients.
• Cinnamon flavoring is not inherently proprietary.
• The general use of nicotine polacrilex in a lozenge is established technology.
• OTC competitors can design around individual excipient ratios.
• A competitor may use a different resin, binder or alkalinizer while maintaining the same therapeutic purpose.

The most defensible intellectual property would likely be a narrow combination claim covering a defined release profile, improved taste, reduced irritation, enhanced stability or a specific resin-excipient interaction.

What formulation improvements create commercial opportunities?

Low-irritation alkalinization

Sodium carbonate is effective but can contribute to an alkaline taste or oral irritation at higher loading. A competitor could explore alternative alkalinizers or buffered systems that maintain nicotine liberation with lower sensory impact. The opportunity is commercially meaningful because irritation and unpleasant taste can reduce adherence.

Improved cinnamon flavor persistence

Cinnamon flavor can produce a strong initial sensory impact but may become harsh during prolonged dissolution. A layered flavor system could separate initial aroma release from sustained flavor release. Encapsulated flavor, controlled-release flavor particles or a lower-irritancy cinnamon composition could support differentiation.

Faster onset without rapid disintegration

Consumers seeking relief from cravings may prefer earlier nicotine availability. The technical challenge is increasing early nicotine release while retaining sufficient lozenge residence time. Porosity control, particle-size engineering, modified compression and resin selection are potential development routes.

Reduced residue and chalkiness

Mannitol-based lozenges can produce a cooling sensation, but the overall tablet may be perceived as chalky if the matrix does not hydrate evenly. Improved particle engineering, granulation and lubricant optimization could produce a smoother mouthfeel.

Moisture and stability control

Nicotine-containing lozenges can be sensitive to moisture, flavor migration and packaging permeability. High-barrier blister packs, desiccant-compatible cartons and improved unit-dose sealing can reduce potency drift and flavor loss. Packaging improvements also create an opportunity for premium positioning.

Sugar-free and dental positioning

A sugar-free platform is commercially compatible with nicotine lozenge use because mannitol and high-intensity sweeteners can replace sucrose. The manufacturer must manage polyol-related gastrointestinal effects and ensure that any dental claims are properly substantiated.

Smaller lozenge formats

A mini-lozenge could improve discretion and portability. It would require control of dose uniformity, handling safety, dissolution time and accidental ingestion risk. A smaller format could appeal to users who dislike the size or mouth residence time of conventional lozenges.

What manufacturing and IP barriers affect market entry?

The manufacturing process is technically straightforward but requires tight controls.

Manufacturing issue	Commercial impact
Uniform nicotine-resin distribution	Prevents dose variability
Alkalinizer dispersion	Controls nicotine release and taste
Compression force	Affects hardness, friability and dissolution
Moisture control	Protects potency, texture and flavor
Flavor retention	Affects consumer acceptance and shelf life
Lubrication	Excess magnesium stearate can slow wetting and dissolution
Packaging barrier	Limits moisture ingress and volatile flavor loss
Child-resistant packaging	Adds compliance cost but reduces safety risk
Cleaning validation	Important because nicotine is pharmacologically active
Supply of nicotine resin	Can become a bottleneck for private-label manufacturers

A competitor does not need to reproduce the exact excipient ratios. It needs a robust, compliant formulation with consistent nicotine delivery and acceptable sensory performance. The biggest operational barrier may be securing pharmaceutical-grade nicotine resin and maintaining flavor stability at scale.

What FDA regulatory issues affect reformulation?

The FDA OTC framework governs active ingredient, strength, route, directions, warnings and labeling. A materially different formulation may require regulatory review if it changes the product’s performance or moves it outside the applicable monograph.

Key regulatory risks include:

• Failure to match the permitted nicotine strength.
• Nonconforming directions or maximum daily use.
• Inadequate warnings for minors, pregnancy, children and accidental ingestion.
• Unsupported claims about faster relief, lower irritation or superior cessation outcomes.
• Dissolution behavior that differs materially from the established product profile.
• Flavor ingredients that create allergen, safety or labeling issues.
• Packaging that fails child-resistant requirements.
• Confusion between a cessation product and a recreational nicotine product.

For a line extension, the most commercially efficient approach is usually to preserve the established 4 mg nicotine dose and change flavor, format, packaging or sensory performance within the relevant FDA boundaries.

Which companies are challenging NICORETTE commercially?

Competition comes from three groups.

Competitor group	Examples of competitive products
Branded nicotine-replacement companies	Nicorette and other established smoking-cessation brands
Generic and private-label manufacturers	Store-brand nicotine lozenges and gums
Alternative nicotine platforms	Nicotine patches, gum, sprays, pouches and prescription cessation products

Haleon controls the NICORETTE brand portfolio following the separation of its consumer-health business from GSK. The branded advantage is strongest in pharmacy recommendation, consumer recognition and broad product-line coverage. Generic manufacturers can compete more effectively on price and retailer economics.

What licensing and partnership opportunities exist?

The most realistic opportunities are commercial and technical rather than licenses to the basic nicotine lozenge concept.

Potential partnership targets include:

• Flavor houses with low-irritation cinnamon systems.
• Nicotine-resin suppliers with improved loading or release characteristics.
• Contract manufacturers experienced in compressed lozenges.
• Packaging companies with high-barrier, child-resistant unit doses.
• Retailers seeking private-label smoking-cessation products.
• Digital cessation platforms that bundle products with adherence support.
• Manufacturers developing combination patch-and-lozenge regimens.

A licensing deal would be most defensible if it covered a measurable technical advantage, such as a patented resin, improved bioavailability, reduced irritation or a validated stability system. A license limited to cinnamon flavor or standard excipients would have weak negotiating value.

How does NICORETTE Cinnamon Surge compare with other nicotine-replacement formats?

Attribute	4 mg lozenge	Nicotine gum	Nicotine patch	Nicotine spray
User-controlled dosing	High	High	Low	High
Discretion	Moderate	Moderate	High	Moderate
Buccal delivery	Yes	Yes	No
Local mouthfeel sensitivity	High	High	None	Moderate
Formulation complexity	Moderate	Moderate	High	High
Flavor importance	Very high	High	Low	High
Generic substitution risk	High	High	High	Moderate
Packaging sensitivity	High	Moderate	Moderate	High

The cinnamon lozenge is best positioned for users who want user-controlled dosing without chewing. Its weakness is sensory dependence: an unpleasant flavor or chalky texture can drive switching even when the pharmacological performance is adequate.

Key Takeaways

• NICORETTE 4 mg Cinnamon Surge uses a conventional nicotine-polacrilex lozenge platform with mannitol, sodium alginate, xanthan gum, sodium carbonate, acesulfame potassium, magnesium stearate and cinnamon flavor.
• The core active ingredient and dosage form are mature technologies with limited broad exclusivity.
• Sodium carbonate, resin loading and gum-based matrix control are the central formulation levers.
• Generic and private-label entry risk is high because competitors can use standard excipients and the OTC pathway.
• The most valuable opportunities involve taste masking, reduced irritation, faster perceived onset, improved mouthfeel, moisture protection and discreet packaging.
• Narrow formulation or process patents may have value, but the NICORETTE trademark and consumer recognition are likely more commercially important than broad formulation exclusivity.
• Regulatory execution under the FDA OTC smoking-cessation framework is a principal barrier to launch.
• A premium reformulation requires a measurable sensory or performance advantage, not simply a different excipient ratio.

FAQs

Is NICORETTE Cinnamon Surge sugar-free?

The formulation uses mannitol and acesulfame potassium rather than conventional sucrose as the principal bulking and sweetening components. Product-specific labeling should be used for final sugar and carbohydrate claims.

Can a company make a generic 4 mg cinnamon nicotine lozenge?

Yes, subject to compliance with FDA requirements for nicotine-replacement products, including active ingredient, strength, labeling, warnings, manufacturing controls and packaging.

Which excipient is most important for nicotine release?

Sodium carbonate is the principal pH-modifying excipient. Its interaction with nicotine polacrilex affects nicotine liberation and buccal absorption.

Can cinnamon flavor create patent protection?

Cinnamon flavor alone is unlikely to provide meaningful broad protection. A technically novel flavor-masking system, sustained-release flavor composition or reduced-irritation formulation could support narrower patent claims.

Is NICORETTE 4 mg Cinnamon Surge protected by a paragraph IV patent challenge?

The product is positioned within the OTC nicotine-replacement framework rather than the standard prescription NDA pathway. A conventional paragraph IV challenge is therefore not the primary expected route for competing entry.

References

1. DailyMed. (n.d.). Nicotine polacrilex 4 mg lozenge, cinnamon: Drug facts and inactive ingredients. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2022). Over-the-counter monograph M006: Smoking cessation. FDA.

3. U.S. Food and Drug Administration. (2023). Nicotine replacement therapy products for smoking cessation. FDA.

4. Haleon plc. (2024). Annual report 2023. Haleon.

5. U.S. Food and Drug Administration. (2024). Substance registration system and inactive ingredient information. FDA.